Dry cleaner’s fight against sons’ rare disease could lead to other life-saving treatments

Phil Milto sat across the table from a wealthy local businessman in disbelief. He’d asked the man to help fund medical
research to find a cure for the rare disease that was killing his eldest son, Nathan–only to be told
that not enough people were affected to merit a contribution.

Milto, an Indianapolis dry cleaner, thanked the man for his time and moved on.

Luckily for countless people with diseases ranging
from Parkinson’s to Alzheimer’s, he didn’t let the rejection derail his efforts.

Years later, the Milto-led Nathan’s Battle Foundation
has evolved into what he calls a not-for-profit biotech company that has raised money and guided research
that resulted in a promising treatment for Batten disease. Now, some of the gene therapy techniques researchers
developed are being applied to other disorders.

"The message I kept trying to tell people all along was that we hoped to develop a treatment
that could be used for a broad spectrum of diseases," Milto said. "Now we see this could have
a worldwide impact."

One of the nation’s leading medical journals recently published the results of the successful foundation-funded treatment
trial, and the U.S. Food and Drug Administration has approved a second round of testing. Milto, 40, is hopeful that within
five to 10 years, the treatment will be available to everyone diagnosed with Batten disease–about 500 to 1,000 people worldwide.

Batten disease is a neurological disorder that
robs children of brain function as it progresses, eventually leading to loss of sight, speech, hearing
and motor skills. The treatment developed with funding from Milto’s foundation involves brain surgery
to inject a gene that will create the enzyme patients lack.

A group in France also is using the Batten treatment platform to develop therapies for other life-threatening
infantile and childhood disorders. And a Parkinson’s disease trial in the United States used the same
gene therapy delivery methods and techniques.

Credit Milto’s relentless drive for a cure–and his use of business skills rarely seen in the
medical and research fields. Milto, a partner in locally based Milto Cleaners, has raised $5.5 million
since the foundation was founded in 1999. He also has guided the research by brokering deals with the
likes of Cornell University, Rutgers University and Boston-based biotech firm Genzyme Corp.

"For someone with no medical, research
or pharmaceutical background to navigate this path is almost unbelievable," said Craig Svensson,
dean of Purdue University’s College of Pharmacy, Nursing and Health Sciences. "Getting this far through the FDA,
especially with an invasive procedure like this one, is extremely complex, not to mention expensive. It’s a Herculean effort."

Giovanna Spinella, a consultant for the office
of rare diseases at the Bethesda, Md.-based National Institutes of Health, said she has never before
seen such a "single-handed effort."

"It’s scary to think where we’d be without Phil and Nathan’s Battle Foundation," said Susan
Balog, a Pittsburgh mother of a child afflicted with Batten disease. "Without the Miltos’ efforts,
we’d have nothing."

Business, meet science

Perhaps one of Milto’s most challenging tasks was convincing people that donations were not about merely helping his family.

"This wasn’t a sick kid story where you
gave money to a cause with no understanding of the return," said Milto, a 1990 Indiana University
business school graduate. "Every donor or investor in our foundation has received a return on their investment
with the delivery of therapies to children. And we think that return could become much broader."

Before Milto’s efforts began, the usual life
span for Batten disease patients was 12 years. Now there is hope for more. Though his health is still
tenuous, Nathan recently turned 14. P.J., another of Milto’s sons who has been diagnosed with the disease,
is 11.

Milto and his wife,
Tricia, also have two healthy sons, Nicholas, 12, and Joey, 4.

Normally, scientists who want to research a disease ask foundations and governmental agencies
for money. Milto’s foundation, however, raised the money first, then pleaded with researchers to help.
Milto also brought together biotech companies and researchers interested in finding broader applications
for the work.

"Most
scientists have no idea how to move basic research from the bench to the clinic, so many discoveries are left in the
lab," he said.

Nathan
was the second child treated with the new gene therapy transfer at Cornell in June 2004. P.J. underwent the brain surgery
needed for the treatment one month later.

Nine of the 10 patients that participated in the first trial are still alive, although the damage caused by the neurological
disease cannot be reversed. If the treatment is applied before the disease progresses, researchers hope to stop it before
the damage occurs.

This
summer, highly respected trade publication Gene Therapy Medical Journal published the results of the first clinical
trials, reporting that the treatment significantly slowed or stopped the disease.

When asked about the progress, Milto takes a
deep breath and exhales slowly.

"It’s been a long journey," he said. "We had a lot of supporters along the way."

He hasn’t forgotten the naysayers he’s met along
the way, either.

"We
want to thank everyone who has been there for us and thank those who have told us that we couldn’t achieve our goals,
which continued to drive us to be successful," Milto said.

Milto isn’t one to get over-emotional, at least not with strangers or newspaper reporters. But
the toll of the journey is obvious in his tone. He knows there are more miles to travel to realize the
full benefit of this sojourn. He sounds both like someone ready to climb the next mountain and someone
ready to pass the torch.

He realizes, too, that time with two of his sons–despite the treatment–still may be short.

"Nathan is still a very sick boy," Milto said.

More money needed

Nathan’s Battle Foundation still owes Cornell $176,878 for the first round of the trials, and
another $2.1 million will be needed for the second round.

With research funded by NBF, Cornell officials think they’ve found an even better way to distribute
treatment more thoroughly through the brain. Milto is hopeful this round of trials could lead to the
treatment of younger Batten children, who could go on to lead "normal" lives.

"Hopefully, this is the beginning of the
end of this disease," Milto said.

Milto’s fund-raising efforts continue next month, with the Eighth Annual Nathan’s Battle Foundation Invitational golf outing
Aug. 28 at Dye’s Walk Country Club in Greenwood.

"Phil and his foundation’s efforts have been non-stop for a decade," said Balog, the Pittsburgh
mother.

Milto insists
he’s not looking for recognition for himself, just the cause.

"The only title I ever wanted was ‘Dad,’" he said.

It seems like a very long time ago that Milto and his supporters from the city’s south side held
their first fund-raiser in August 1999. The golf outing raised $14,000.

In 1997, 3-year-old Nathan suddenly started to lose his balance and had vision problems. In 1999,
he was diagnosed with Batten disease.

"Our doctors told us to go home and enjoy the time we had with him," Milto said.

He refused to heed their advice.

Instead, he wrote out a business plan, the initial
copy on the back of a napkin. Then he refined it and put it to work.

"For my wife and I, our kids are the most important things to us," Milto said. "Our
job is to try to make their lives better, in ways big or small, whether it’s tucking them in safely at
night or developing a new drug. That’s what we’ve dedicated our lives to."

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.